NFE2L2 and hepatocellular carcinoma: KRAL competes with the 3’UTR of Keap1 mRNA to bind miR-141; this competition promotes Keap1 expression and inhibits the Nrf2-ARE pathway, thus leading to a reversal of 5-FU resistance in HCC cells.